CLINICAL_TRIALS
trial_result
· 2021-04-08
Clinical Trial Update: Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma [Phase 2]
Summary
Phase 2 trial evaluating NY-ESO-1 ISCOMATRIX in high-risk, resected melanoma has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ludwig Institute for Cancer Research | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2021-04-08